デフォルト表紙
市場調査レポート
商品コード
992796

がんバイオマーカーの世界市場

Cancer Biomarkers

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 384 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

がんバイオマーカーの世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 384 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のがんバイオマーカーの市場規模は、分析期間(2020年~2027年)に13%のCAGRで成長する見通しで、2020年の171億米ドルから、2027年には404億米ドルに達すると予測されています。

当レポートで分析されているセグメントの1つである乳がんは、分析期間中に13.8%のCAGRで成長し、121億米ドルに達すると予測されています。

当レポートは、世界のがんバイオマーカー市場について調査しており、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • Abbott Laboratories
  • Agilent Technologiesent
  • Becton, Dickinson and Company
  • Biomerieux Sant
  • Bio-Rad Laboratories
  • Danaher Corporation
  • GE Healthcare
  • Hologic
  • Illuminat
  • Merck & Co.
  • Myriad Genetics
  • Qiagen N.V.
  • Quest Diagnostics
  • Roche Diagnostics
  • Sysmex Corporation
  • Thermo Fisher Scientific

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と推進要因
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

IV. 競合

  • 企業プロファイル:33社
目次
Product Code: MCP21409

Abstract:

Global Cancer Biomarkers Market to Reach $40.4 Billion by 2027

Amid the COVID-19 crisis, the global market for Cancer Biomarkers estimated at US$17.1 Billion in the year 2020, is projected to reach a revised size of US$40.4 Billion by 2027, growing at a CAGR of 13% over the analysis period 2020-2027. Breast Cancer, one of the segments analyzed in the report, is projected to record a 13.8% CAGR and reach US$12.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Colorectal Cancer segment is readjusted to a revised 14.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $4.6 Billion, While China is Forecast to Grow at 17.1% CAGR

The Cancer Biomarkers market in the U.S. is estimated at US$4.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$9 Billion by the year 2027 trailing a CAGR of 17.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.2% and 11.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.3% CAGR.

Cervical Cancer Segment to Record 11.2% CAGR

In the global Cervical Cancer segment, USA, Canada, Japan, China and Europe will drive the 10.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2 Billion in the year 2020 will reach a projected size of US$4.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6 Billion by the year 2027, while Latin America will expand at a 12.7% CAGR through the analysis period.

Select Competitors (Total 33 Featured) -

  • Abbott Laboratories
  • Agilent Technologiesent
  • Becton, Dickinson and Company
  • Biomerieux Sant
  • Bio-Rad Laboratories
  • Danaher Corporation
  • GE Healthcare
  • Hologic
  • Illuminat
  • Merck & Co.
  • Myriad Genetics
  • Qiagen N.V.
  • Quest Diagnostics
  • Roche Diagnostics
  • Sysmex Corporation
  • Thermo Fisher Scientific

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Cervical Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Metabolic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Metabolic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Metabolic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Other Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Other Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Other Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Genetic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Genetic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Genetic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Proteomic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Proteomic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Proteomic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Epigenetic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Epigenetic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Epigenetic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 40: World Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 41: World Historic Review for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: World 15-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 43: World Current & Future Analysis for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 44: World Historic Review for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: World 15-Year Perspective for Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 46: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 47: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 49: USA Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: USA Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: USA 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 52: USA Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: USA Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: USA 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 55: USA Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: USA Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: USA 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 58: Canada Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Canada Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Canada 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 61: Canada Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Canada Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Canada 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 64: Canada Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Canada Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Canada 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 67: Japan Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Japan Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Japan 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 70: Japan Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Japan Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Japan 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 73: Japan Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Japan Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Japan 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 76: China Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: China Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: China 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 79: China Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: China Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: China 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 82: China Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: China Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: China 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 85: Europe Current & Future Analysis for Cancer Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 86: Europe Historic Review for Cancer Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Europe 15-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 88: Europe Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Europe Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Europe 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 91: Europe Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Europe Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Europe 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 94: Europe Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Europe Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Europe 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 97: France Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: France Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: France 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 100: France Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: France Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: France 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 103: France Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: France Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: France 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 106: Germany Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Germany Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Germany 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 109: Germany Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Germany Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Germany 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 112: Germany Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Germany Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Germany 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 115: Italy Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Italy Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Italy 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 118: Italy Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Italy Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Italy 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 121: Italy Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Italy Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: Italy 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 124: UK Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: UK Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: UK 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 127: UK Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: UK Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: UK 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 130: UK Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: UK Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: UK 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 133: Spain Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Spain Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Spain 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 136: Spain Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Spain Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Spain 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 139: Spain Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Spain Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Spain 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 142: Russia Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Russia Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Russia 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 145: Russia Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Russia Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Russia 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 148: Russia Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Russia Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Russia 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 151: Rest of Europe Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Rest of Europe Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Rest of Europe 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 154: Rest of Europe Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Rest of Europe Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: Rest of Europe 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 157: Rest of Europe Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Rest of Europe Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: Rest of Europe 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 160: Asia-Pacific Current & Future Analysis for Cancer Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 161: Asia-Pacific Historic Review for Cancer Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: Asia-Pacific 15-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 163: Asia-Pacific Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Asia-Pacific Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: Asia-Pacific 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 166: Asia-Pacific Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Asia-Pacific Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: Asia-Pacific 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 169: Asia-Pacific Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Asia-Pacific Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: Asia-Pacific 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 172: Australia Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Australia Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: Australia 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 175: Australia Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Australia Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: Australia 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 178: Australia Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Australia Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: Australia 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 181: India Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 182: India Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 183: India 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 184: India Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 185: India Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 186: India 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 187: India Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: India Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 189: India 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 190: South Korea Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 191: South Korea Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 192: South Korea 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 193: South Korea Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 194: South Korea Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 195: South Korea 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 196: South Korea Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 197: South Korea Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 198: South Korea 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 199: Rest of Asia-Pacific Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Rest of Asia-Pacific Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 201: Rest of Asia-Pacific 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 202: Rest of Asia-Pacific Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Rest of Asia-Pacific Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 204: Rest of Asia-Pacific 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 205: Rest of Asia-Pacific Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Rest of Asia-Pacific Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 207: Rest of Asia-Pacific 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 208: Latin America Current & Future Analysis for Cancer Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 209: Latin America Historic Review for Cancer Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 210: Latin America 15-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 211: Latin America Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Latin America Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 213: Latin America 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 214: Latin America Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Latin America Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 216: Latin America 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 217: Latin America Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Latin America Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 219: Latin America 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 220: Argentina Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Argentina Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 222: Argentina 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 223: Argentina Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Argentina Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 225: Argentina 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 226: Argentina Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 227: Argentina Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 228: Argentina 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 229: Brazil Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 230: Brazil Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 231: Brazil 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 232: Brazil Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 233: Brazil Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 234: Brazil 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 235: Brazil Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 236: Brazil Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 237: Brazil 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 238: Mexico Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 239: Mexico Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 240: Mexico 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 241: Mexico Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 242: Mexico Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 243: Mexico 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 244: Mexico Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 245: Mexico Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 246: Mexico 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 247: Rest of Latin America Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 248: Rest of Latin America Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 249: Rest of Latin America 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 250: Rest of Latin America Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 251: Rest of Latin America Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 252: Rest of Latin America 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 253: Rest of Latin America Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Rest of Latin America Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 255: Rest of Latin America 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 256: Middle East Current & Future Analysis for Cancer Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 257: Middle East Historic Review for Cancer Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 258: Middle East 15-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 259: Middle East Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Middle East Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 261: Middle East 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 262: Middle East Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 263: Middle East Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 264: Middle East 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 265: Middle East Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Middle East Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 267: Middle East 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 268: Iran Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Iran Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 270: Iran 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 271: Iran Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Iran Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 273: Iran 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 274: Iran Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Iran Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 276: Iran 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 277: Israel Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 278: Israel Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 279: Israel 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 280: Israel Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 281: Israel Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 282: Israel 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 283: Israel Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 284: Israel Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 285: Israel 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 286: Saudi Arabia Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 287: Saudi Arabia Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 288: Saudi Arabia 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 289: Saudi Arabia Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 290: Saudi Arabia Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 291: Saudi Arabia 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 292: Saudi Arabia Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 293: Saudi Arabia Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 294: Saudi Arabia 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 295: UAE Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 296: UAE Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 297: UAE 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 298: UAE Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 299: UAE Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 300: UAE 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 301: UAE Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 302: UAE Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 303: UAE 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 304: Rest of Middle East Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 305: Rest of Middle East Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 306: Rest of Middle East 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 307: Rest of Middle East Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 308: Rest of Middle East Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 309: Rest of Middle East 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 310: Rest of Middle East Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 311: Rest of Middle East Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 312: Rest of Middle East 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 313: Africa Current & Future Analysis for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 314: Africa Historic Review for Cancer Biomarkers by Type - Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 315: Africa 15-Year Perspective for Cancer Biomarkers by Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer and Other Types for the Years 2012, 2020 & 2027
    • TABLE 316: Africa Current & Future Analysis for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 317: Africa Historic Review for Cancer Biomarkers by Biomolecule - Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 318: Africa 15-Year Perspective for Cancer Biomarkers by Biomolecule - Percentage Breakdown of Value Sales for Metabolic Biomarkers, Other Biomolecules, Genetic Biomarkers, Proteomic Biomarkers and Epigenetic Biomarkers for the Years 2012, 2020 & 2027
    • TABLE 319: Africa Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 320: Africa Historic Review for Cancer Biomarkers by Application - Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 321: Africa 15-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Drug Discovery & Development, Personalized Medicine and Other Applications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 33